Orbimed Advisors - THERAVANCE BIOPHARMA INC ownership

THERAVANCE BIOPHARMA INC's ticker is TBPH and the CUSIP is G8807B106. A total of 125 filers reported holding THERAVANCE BIOPHARMA INC in Q3 2022. The put-call ratio across all filers is 0.59 and the average weighting 0.2%.

Quarter-by-quarter ownership
Orbimed Advisors ownership history of THERAVANCE BIOPHARMA INC
ValueSharesWeighting
Q2 2022$12,414,000
-60.1%
1,370,250
-57.9%
0.22%
-55.4%
Q1 2022$31,115,000
-52.9%
3,254,713
-45.5%
0.50%
-40.5%
Q4 2021$66,019,000
+51.3%
5,974,535
+1.3%
0.85%
+77.2%
Q3 2021$43,624,000
-34.2%
5,895,159
+29.2%
0.48%
-28.5%
Q2 2021$66,270,000
-47.8%
4,564,045
-26.6%
0.67%
-43.6%
Q1 2021$126,932,000
+14.9%
6,219,1100.0%1.19%
+22.8%
Q4 2020$110,514,000
+20.2%
6,219,1100.0%0.97%
-16.3%
Q3 2020$91,950,000
+71.5%
6,219,110
+143.5%
1.16%
+53.1%
Q2 2020$53,618,000
+996.7%
2,554,470
+1107.5%
0.76%
+820.7%
Q1 2020$4,889,000211,5450.08%
Other shareholders
THERAVANCE BIOPHARMA INC shareholders Q3 2022
NameSharesValueWeighting ↓
Madison Avenue Partners, LP 7,012,226$71,104,00015.26%
Newtyn Management, LLC 2,495,860$25,308,0005.56%
Chescapmanager LLC 1,160,503$11,768,0002.74%
Baupost Group 13,419,226$136,071,0002.35%
Weiss Asset Management LP 7,457,060$75,615,0001.86%
Park West Asset Management LLC 1,919,354$19,462,0001.38%
Cannon Global Investment Management, LLC 65,000$659,0001.06%
Oasis Management Co Ltd. 296,960$3,011,0000.51%
Rubric Capital Management LP 356,100$3,611,0000.18%
Sagefield Capital LP 51,600$523,0000.17%
View complete list of THERAVANCE BIOPHARMA INC shareholders